Relmada Therapeutics Azioni (NASDAQ: RLMD)

Ultime notizie per Relmada Therapeutics (NASDAQ:RLMD) Azioni

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Lotus continues to achieve top-rate growth among traditional luxury car brands, delivering 7,543 vehicles1&nbsp;in the first nine months of 2024, representing a year-on-year increase of&nbsp;134%. Global allocation in terms of deliveries remained well-distributed, with Europe, China, North America and the Rest of the World regions each contributing about&nbsp;20-35%&nbsp;of the total deliveries. In the&nbsp;third quarter&nbsp;of 2024, Emeya (GT, Sedan) was delivered to Europe, whilst Eletre (SUV) reached markets including the GCC, Japan and Korea.

News

Reported Earlier, Lotus Technology Reports 134% YoY Vehicle Delivery Surge In First Nine Months Of 2024

Macro Economic Events

Econ #s

Economics

U.K. Retail Sales (YoY) For September 3.9% Vs. 3.2% Est.; 2.3% (Revised) Prior

U.K. Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.0% Prior

U.K. Core Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.1% Prior

U.K. Core Retail Sales (YoY) For September 4.0% Vs. 3.2% Est.; 2.2% (Revised) Prior

Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Co-CEO&nbsp;Ted Sarandos on Thursday outlined why the streaming giant continues to hold an edge over YouTube, a subsidiary of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: During Netflix&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter earnings</a> call, a question about&nbsp;YouTube&#8217;s growing share of TV&nbsp;consumption was raised.
In response, Sarandos highlighted Netflix&#8217;s commitment to investing in premium content to increase viewer engagement, stating, &#8220;Netflix is the best place&nbsp;for premium stories because we&#8217;re&nbsp;the home to the best&nbsp;storytellers.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
Regarding YouTube, he said, &#8220;When I look at YouTube specifically, I&#8217;d say look, we compete directly with YouTube for people&#8217;s time, for the time they spend on that TV screen. But we have very different strengths.&#8221;
Another, Netflix Co-CEO Greg Peters added that Netflix plays a crucial role for consumers seeking high-quality movies and TV shows, and for creators looking for partners willing to share the inherent risks of bringing stories to life.
&#8220;A Hundred Years of Solitude, Senna, both coming from Latin America, which are huge, ambitious projects. It&#8217;s hard to imagine how those kind of big creative bets would be possible with YouTube&#8217;s model,&#8221; Peters stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Netflix&#8217;s third-quarter financial results showed a 15% year-over-year increase in revenue, beating Street consensus estimates.
Moreover, Netflix&#8217;s recent foray into live sports programming indicates a strategic shift from its traditional on-demand model. This move aims to capture high-impact moments and the <a href="https://www.benzinga.com/general/entertainment/24/10/41395213/netflixs-200b-hour-problem-why-live-sports-are-just-a-drop-in-the-streaming-ocean">excitement of global live events</a>, further enhancing viewer engagement.
During the <a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game" target="_blank" rel="noreferrer noopener">second-quarter earnings</a> call, Netflix executives were asked questions about YouTube.
At the time, Sarandos&nbsp;said, &#8220;So our two services — us and YouTube represent about 50% of all streaming to the TV in the U.S. and we use the U.S. only because that's where we have the data.&#8221;
&#8220;So really what we're focused on here is focusing ourselves on that other 80% of total TV time that isn't going to either us or YouTube,&#8221; he said in July.
Sarandos <a href="https://www.benzinga.com/general/entertainment/24/07/39853498/netflix-aims-to-capture-broader-tv-market-sees-youtube-as-both-competitor-and-partner-we-ki">reiterated Netflix&#8217;s commitment to focus</a> on the remaining 80% of the market during the third-quarter call too.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chips In US For iPhone Maker</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Entertainment

Equities

Markets

Tech

General

GOOG

GOOGL

NFLX

Netflix's Ted Sarandos Downplays Concerns Of YouTube's Growing Share Of TV Consumption: 'We're The Home To The Best Storytellers'

Orders and deliveries
In Q3, net order intake decreased by 8% to 43,234 trucks and deliveries decreased by 16% to 46,266 units. Deliveries of heavyduty trucks decreased by 9%, of medium-duty trucks by 21% and of light-duty trucks by 61%.

Earnings

VLVLY

Volvo's Q3 Saw 8% Drop In Net Order Intake To 43,234 Trucks, With Deliveries Down 16% To 46,266 Units

Volvo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLVLY#OTC">VLVLY</a>) reported quarterly earnings of $0.47 per share. This is a 26.18 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $11.22 billion in sales this quarter. This is a 8.38 percent decrease over sales of $12.25 billion the same period last year

VLVCY

Volvo Q3 EPS $0.47 Down From $0.64 YoY, Sales $11.22B Down From $12.25B YoY

Sam Altman&#8217;s cryptocurrency-based <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37573206/sam-altmans-worldcoin-halts-id-verification-in-spain-amid-legal-tussle">identity verification project</a> Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>) will now be known as &#8220;World.&#8221; Apart from the rebrand, the team also announced the launch of World Chain, an Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-based Layer-2 network.
What Happened: At an event on Thursday, OpenAI CEO Altman, along with the other executives tied to the project, unveiled several new developments.
The team outlined their plans for &#8220;Orb 2.0,&#8221; an enhanced version of the biometric imaging device that the project uses to collect people's iris in exchange for WLD tokens.
The team also announced the introduction of World Chain, a blockchain that can be customized to meet its specific demands. With 15 million human data points, it was dubbed the &#8220;largest blockchain of humans on day one.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41319774/if-you-invested-1-000-in-bitcoin-when-warren-buffett-called-it-rat-poison-squared-heres-ho?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If You Invested $1,000 In Bitcoin When Warren Buffett Called It &#8216;Rat Poison Squared,&#8217; Here&#8217;s How Much You</a>
Why It Matters: Sam Altman launched the Worldcoin project last year amid significant media attention. 
However, the positive publicity soon transformed into negative publicity as concerns over personal data privacy surfaced. The project has been banned in&nbsp;<a href="https://www.benzinga.com/markets/asia/24/05/38981228/sam-altman-founded-worldcoin-shown-the-door-in-hong-kong-over-privacy-concerns" target="_blank" rel="noreferrer noopener">Hong Kong</a>, Kenya, and&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39176283/sam-altman-founded-worldcoins-suspension-extended-in-spain-crypto-plunges-55-since-march-p" target="_blank" rel="noreferrer noopener">Spain</a>. 
The persistent scrutiny affected the performance of the WLD token, causing it to plunge 40% year-to-date. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Keynote: a new world" width="500" height="281" src="https://www.youtube.com/embed/Ey5bSeUeqqU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: As of this writing, WLD was exchanging hands at $2.21, losing 1.95% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41328586/mark-cuban-dismisses-dogecoin-founders-concerns-kamala-harris-is-night-and-day-away-from-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Arrest Made In SEC X Account Hack Prior To Bitcoin ETF Approval, FBI Says Phone Used To &#8216;Manipulate Financial Markets&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Worldcoin<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$WLD

Sam Altman-Founded Worldcoin Is Changing Its Name To 'World' And Launching Its Own Blockchain — WLD Token's Fortunes Set To Soar?

Reported Earlier, Chinese Unemployment Rate For September 5.1% Vs. 5.3% Est.; 5.3% Prior

Reported Earlier, China Industrial Production Year to Date (YoY) For September 5.8% Vs. 5.8% Prior

Reported Earlier, China Industrial Production (YoY) For September 5.4% Vs. 4.6% Est.; 4.5% Prior

Reported Earlier, China Gross Domestic Product (GDP) Year to Date (YoY) For Q3 4.8% Vs. 5.0% Prior

Reported Earlier, China Gross Domestic Product (YoY) For Q3 4.6% Vs. 4.6% Est.; 4.7% Prior

Reported Earlier, China Gross Domestic Product (QoQ) For Q3 0.9% Vs. 1.0% Est.; 0.7% Prior

Reported Earlier, China Fixed Asset Investment (YoY) For September 3.4% Vs. 3.3% Est.; 3.4% Prior

Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has launched its new desktop trading platform, Robinhood Legend, at the HOOD Summit 2024, signaling a significant shift from its <a href="https://www.benzinga.com/fintech/24/10/41371235/robinhood-announces-futures-trading-index-options-trading">mobile-first approach</a> to a more comprehensive wealth management platform.
What Happened: Chief Brokerage Officer Steve Quirk emphasized the need for this transition, stating, &#8220;About 50% of all retail trading happens on a mobile device and about 50% of it happens on a desktop. We, up to this point, had only been competing on the mobile front. Now we have an alternative.&#8221; Quirk <a href="https://youtu.be/FyaBFs1dZZI?feature=shared">said</a> this in an appearance on CNBCOvertime.
Robinhood Legend is designed to appeal to more sophisticated retail investors, featuring advanced charting capabilities with up to eight simultaneous charts and enhanced technical indicators. 
CEO Vlad Tenev highlighted the initial success of the platform, announcing that the first thousand early access spots were claimed in under a minute, indicating robust demand among users.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41395673/google-reshuffles-search-leadership-while-navigating-ai-threat-to-core-business">Google Reshuffles Search Leadership While Navigating AI Threat To Core Business</a>
Why It Matters: This development follows a series of strategic moves by Robinhood to expand its offerings. The company recently announced the launch of <a href="https://www.benzinga.com/fintech/24/10/41371235/robinhood-announces-futures-trading-index-options-trading">futures trading and index options trading</a> at the HOOD Summit 2024. This was seen as a major expansion of the platform&#8217;s offerings.
Robinhood&#8217;s acquisition of Bitstamp is also expected to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41391989/exclusive-robinhoods-bitstamp-deal-will-drive-growth-exec-says-what-was-good-for-stocks-we">drive growth in its crypto offerings</a>. The company&#8217;s General Manager for Robinhood Crypto, Johann Kerbrat, highlighted the potential impact of this acquisition on the company&#8217;s crypto products.
Robinhood&#8217;s growth has been a topic of <a href="https://www.benzinga.com/markets/options/24/10/41389775/exclusive-cboe-ceo-says-robinhood-growth-an-eye-opener-unpredictable-2024-election-could-increase">discussion in the industry</a>, with CBOE CEO Fred Tomczyk describing it as &#8220;an eye-opener&#8221;. The company&#8217;s expansion into desktop trading is expected to further strengthen its position in the market.
Price Action: Robinhood&#8217;s stock closed at $26.32 on Thursday, down 2.27% for the day. In after-hours trading, the stock saw a slight increase of 0.38%. Year to date, Robinhood&#8217;s stock has experienced growth of 112.77%, according to <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41308908/man-who-accidentally-threw-hard-drive-containing-8-000-bitcoins-worth-half-a-billion-dolla?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Man Who Accidentally Threw Hard Drive Containing 8,000 Bitcoins Worth Half A Billion Dollars In Landfill Sues Local City Council For Not Excavating The Site</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

HOOD

Robinhood Aims To Capture Beyond 50% Of Mobile Traders With Legend Desktop Platform: 'Now We Have An Alternative'

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan National Consumer Price Index (MoM) For September -0.3% Vs. 0.5% Prior

Reported Earlier, Japan National Core Consumer Price Index (YoY) For September 2.4% Vs. 2.3% Est.; 2.8% Prior

In a recent interview, former President Donald Trump advocated for a significant increase in import tariffs, a move that was slammed by Nobel winning economist Paul Krugman in a recent opinion piece.
What Happened: Trump, known for imposing substantial tariffs during his presidency, is now suggesting tariffs as high as 20 percent, including a 60 percent tariff on imports from China. Economists have voiced their opposition to these proposals, warning that such high tariffs could harm the economy, according to Krugman in his New York Times column. He said he shared a similar view.
The economist also shared the column through X and asked, &#8220;Are Trump's tariff ideas really that bad? No, they're worse.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Are Trump's tariff ideas really that bad? No, they're worse <a href="https://t.co/AgDoAYoVfQ">https://t.co/AgDoAYoVfQ</a>
&mdash; Paul Krugman (@paulkrugman) <a href="https://twitter.com/paulkrugman/status/1847062351997984849?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The former president believes that these high tariffs would reduce U.S. trade deficits and stimulate domestic manufacturing. However, this approach has been widely criticized by economists, who argue that the tariffs would not achieve these goals.
Opining on why Trump favored Tariffs, Krugman wrote, &#8220;It has never been entirely clear why Trump has a thing for tariffs. My guess is that he sees everything in terms of winners, losers and punishment.&#8221;
Trump&#8217;s proposed tariffs, if implemented, could potentially turn the clock back 90 years, raising overall tariffs to levels not seen since the era of the Smoot-Hawley Tariff Act.
Trump&#8217;s proposed tariffs were framed as a plan, they were likely to raise living costs by about 3 to 4 percent, disproportionately affecting middle- and lower-income families. Economists generally agreed that these tariffs would not boost American manufacturing or reduce the trade deficit, and could ultimately harm the economy by increasing global poverty and creating market fragmentation, said Krugman.
&#8220;What the tariffs would do is shrink our economy. They would cause us to sell less of the goods we currently export — that is, stuff we're relatively good at producing — and more stuff we aren't that good at producing. The effect would be to make the economy less efficient and poorer,&#8217; wrote the Economist.
He warned, &#8220;The Trump tariffs could cause a spike in global poverty — and, it's easy to imagine, global conflict.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Financial Sector Hits Record Highs As Goldman Sachs, Bank of America, Citi Beat Q3 Earnings Expectations</a>
Why It Matters: Trump&#8217;s tariff strategy has been a topic of discussion among economists and business leaders. <a href="https://www.benzinga.com/general/politics/24/10/41371990/trump-cant-impose-tariffs-on-china-says-peter-schiff-he-can-only-impose-tariffs-on-americans-who">Peter Schiff</a>, a renowned economist, criticized Trump&#8217;s approach, stating that tariffs would only affect Americans who buy Chinese products.
Similarly, billionaire Mark Cuban <a href="https://www.benzinga.com/news/24/10/41348822/mark-cuban-says-he-knows-what-trump-wants-to-achieve-with-tariffs-but-the-ex-president-has-no-idea-w">expressed his skepticism</a> about Trump&#8217;s approach to revitalizing U.S. manufacturing through tariffs. In a post, Cuban argued that Trump does not understand what it takes to achieve his goals.
Trump defended his tariff strategy during an <a href="https://www.benzinga.com/general/politics/24/10/41344136/trump-goes-on-the-defense-about-massive-effect-of-tariffs-economic-growth-putin-relationship-djt">interview</a> at the Economic Club of Chicago, stating that tariffs have a &#8220;massive effect.&#8221;
Image via Flickr
Read Next: 
Read Next: 
<ul>
<li><a href="EXCLUSIVE: Robinhood's Bitstamp Deal Will Drive Growth, Exec Says: 'What Was Good For Stocks ... We Brought Into Crypto'">EXCLUSIVE: Robinhood&#8217;s Bitstamp Deal Will Drive Growth, Exec Says: &#8216;What Was Good For Stocks … We Brought Into Crypto&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Paul Krugman Warns Trump's Tariff Plan Could Rewind Economic Progress 90 Years and Ignite Global Conflict: 'He Sees Everything In Terms Of Winners, Losers And Punishment'

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

In a report released on June 6, Uy Ear from Mizuho Securities reiterated a Buy rating on Relmada Therapeutics (RLMD – Research Report), with a pric...

Relmada Therapeutics' REL-1017: Strong Buy on Robust Trial Design and Market Potential

Relmada Therapeutics GAAP EPS of -$0.59 beats by $0.24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) just reported results for the second quarter of 2024.<ul><li>Relmada Therapeutics reported earnings per share of -59 cents. This was above the analyst estimate for EPS of -83 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rlmd-stock-earnings-relmada-therapeutics-for-q2-of-2024/">RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024

Marc Goodman, an analyst from Leerink Partners, maintained the Buy rating on Relmada Therapeutics (RLMD – Research Report). The associated price ta...

Optimistic Outlook for Relmada Therapeutics: Strategic Trial Enhancements and Solid Financial Position

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relmada Therapeutics (RLMD – Research Report) and Ne...

Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)

Relmada Therapeutics files to sell $250M mixed securities shelf

Mizuho Securities analyst Uy Ear maintained a Buy rating on Relmada Therapeutics (RLMD – Research Report) on September 11. The company's shares clo...

Comments

Relmada Therapeutics

Notizie

Ultime notizie per Relmada Therapeutics (NASDAQ:RLMD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO